FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/5/2026
Rigel Pharma (NASDAQ: RIGL) reported Q3 EPS of ($0.14), $0.01 better than the analyst estimate of ($0.15).
On October 2, 2017, Rigel announced that the U.S. Food and Drug Administration (FDA) is not currently planning on holding an Oncology Drugs Advisory Committee (ODAC) meeting to... More
